Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Cancer organoids to model therapy response: Cancer organoids are miniature, three-dimensional cell culture models that can be made from primary patient tumors and studied in the laboratory. Vlachogiannis et al. asked whether such “tumor-in-a-dish” approaches can be used to predict drug responses in the clinic. They generated a live organoid biobank from patients with metastatic gastrointestinal cancer who had previously been enrolled in phase I or II clinical trials. This allowed the authors to compare organoid drug responses with how the patient actually responded in the clinic. Encouragingly, the organoids had similar molecular profiles to those of the patient tumor, reinforcing their value as a platform for drug screening and development. Science , this issue p. 920
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a living biobank of cancer PDOs from patients with metastatic and pre-treated colorectal and gastroesophageal cancer shows strong morphological, genotypic and spatiotemporal similarities between the primary tumour and the PDOs123.”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“revealing strong correlations between in vitro and in vivo drug responses against cancer in the gastrointestinal tract123, bladder124, ovary125, rectum126 and pancreas127,128.”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“PDOs reliably predicted treatment responses in patients, with 100% sensitivity, 93% specificity, 88% positive predictive value and 100% negative predictive value, including response to taxanes and anti-EGFR antibodies”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“These models have been particularly important in the search for anticancer compounds as they can predict patient outcomes in phase 1/2 clinical trials for gastrointestinal cancer [55].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [55]
In the citing paper
“these primary tumor clusters significantly triggered the angiogenic sprouting of HUVECs.”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [113]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
HISAT: a fast spliced aligner with low memory requirements
Kim, D., Langmead, B., & Salzberg, S. L. (2015) · Nature Methods · doi:10.1038/nmeth.3317 · Cited by 24,112
StringTie enables improved reconstruction of a transcriptome from RNA-seq reads
Pertea, M., Pertea, G. M., Antonescu, C. M., Chang, T.-C., Mendell, J. T., & Salzberg, S. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3122 · Cited by 14,298
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000412 · Cited by 7,300
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Cited by
Items 201–300 of 1,001
Patient-derived tumor-like cell clusters for drug testing in cancer therapy
Yin, S., Xi, R., Wu, A., Wang, S., Li, Y., Wang, C., Tang, L., Xia, Y., Yang, D., Li, J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz1723 · Cited by 109
Haderk, F., Chou, Y.-T., Cech, L., Fernández-Méndez, C., Yu, J., Olivas, V., Meraz, I. M., Barbosa Rabago, D., Kerr, D. L., Gomez, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47423-0 · Cited by 103
Driehuis, E., Spelier, S., Beltrán Hernández, I., de Bree, R., M. Willems, S., Clevers, H., & Oliveira, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111880 · Cited by 104
Latacz, E., Höppener, D. J., Bohlok, A., Leduc, S., Tabariès, S., Moro, C. F., Lugassy, C., Nyström, H., Bozóky, B., Floris, G., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01859-7 · Cited by 114
Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer
Boilève, A., Cartry, J., Goudarzi, N., Bedja, S., Mathieu, J. R. R., Bani, M. A., Nicolle, R., Mouawia, A., Bouyakoub, R., Nicotra, C., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.05.032 · Cited by 112
Dissection of gastric cancer heterogeneity for precision oncology
Ho, S. W. T., & Tan, P. B. O. (2019) · Cancer Science · doi:10.1111/cas.14191 · Cited by 109
SUMO pathway inhibition targets an aggressive pancreatic cancer subtype
Biederstädt, A., Hassan, Z., Schneeweis, C., Schick, M., Schneider, L., Muckenhuber, A., Hong, Y., Siegers, G., Nilsson, L. M., Wirth, M., et al. (2020) · Gut · doi:10.1136/gutjnl-2018-317856 · Cited by 112
Patient-derived melanoma organoid models facilitate the assessment of immunotherapies
Ou, L., Liu, S., Wang, H., Guo, Y., Guan, L., Shen, L., Luo, R., Elder, D. E., Huang, A. C. C., Karakousis, G. C., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104614 · Cited by 108
Zhao, Y., Li, S., Zhu, L., Huang, M., Xie, Y., Song, X., Chen, Z., Lau, H. C.-H., Sung, J. J.-Y., Xu, L., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101627 · Cited by 141
“8,9 In particular, PDOs could accurately preserve and recapitulate both the genetic landscape and histopathological features of their originated tumors, implicating their potential application in personalized cancer treatment.”
Drug resistance in cancer: molecular mechanisms and emerging treatment strategies
Li, J., Hu, J., Yang, Y., Zhang, H., Liu, Y., Fang, Y., Qu, L., Lin, A., Luo, P., Jiang, A., et al. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00352-w · Cited by 146
“Additionally, most models overlook the microbiome’s influence on drug metabolism and immune activation, as illustrated by germ-free conditions abolishing the microbiota-dependent efficacy of CTLA-4 blockade [340, 341].”
Evaluation of colorectal cancer subtypes and cell lines using deep learning
Ronen, J., Hayat, S., & Akalin, A. (2019) · Life Science Alliance · doi:10.26508/lsa.201900517 · Cited by 99
“Patientderived tumor models have been shown to predict in patients’ response to treatments (10), and so by finding best-matching tumor”
BackgroundKidney Organoids and Tubuloids
Yengej, F. A. Y., Jansen, J., Rookmaaker, M. B., Verhaar, M. C., & Clevers, H. C. (2020) · Cells · doi:10.3390/cells9061326 · Cited by 119
“Drug efficacy screening was previously shown to correlate well with clinical outcomes in intestinal tumor organoids [115].”
ResultOrganoids in image-based phenotypic chemical screens
Lukonin, I., Zinner, M., & Liberali, P. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00641-8 · Cited by 99
Organoids: a novel modality in disease modeling
Heydari, Z., Moeinvaziri, F., Agarwal, T., Pooyan, P., Shpichka, A. I., Maiti, T. K., Timashev, P. S., Baharvand, H., & Vosough, M. (2021) · Bio-Design and Manufacturing · doi:10.1007/s42242-021-00150-7 · Cited by 111
“These living biobanks of canceroids from gastrointestinal cancers recapitulated the patient response to anti-cancer agents in clinical trials [34, 35].”
BackgroundPatient-derived organoids in translational oncology and drug screening
Yang, R., & Yu, Y. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216180 · Cited by 99
Intestinal organoids: A new paradigm for engineering intestinal epithelium in vitro
Rahmani, S., Breyner, N. M., Su, H.-M., Verdu, E. F., & Didar, T. F. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.12.006 · Cited by 98
Airway organoids as models of human disease
van der Vaart, J., & Clevers, H. C. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13075 · Cited by 106
The Use of Stem Cell-Derived Organoids in Disease Modeling: An Update
Azar, J., Bahmad, H. F., Daher, D., Moubarak, M. M., Hadadeh, O., Monzer, A., Al Bitar, S., Jamal, M., Al-Sayegh, M., & Abou-Kheir, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147667 · Cited by 96
Patient-derived organoids: a promising model for personalized cancer treatment
Yang, H., Sun, L., Liu, M., & Mao, Y. (2018) · Gastroenterology Report · doi:10.1093/gastro/goy040 · Cited by 96
“Hematoxylin and eosin staining shows that PDOs share morphological features with the primary tumor and immunohistochemistry markers used in the diagnosis of specific tumors show that the expression pattern of the tumor is maintained in PDOs [7].”
BackgroundInfluentialDing, R., Chen, P., Rajendran, B. K., Lyu, X., Wang, H., Bao, J., Zeng, J., Hao, W., Sun, H., Wong, A. H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23379-3 · Cited by 102
Data analysis guidelines for single-cell RNA-seq in biomedical studies and clinical applications
Su, M., Pan, T., Chen, Q.-Z., Zhou, W., Gong, Y., Xu, G., Yan, H.-Y., Li, S., Shi, Q.-Z., Zhang, Y., et al. (2022) · Military Medical Research · doi:10.1186/s40779-022-00434-8 · Cited by 144
“Patient-derived organoid models are currently being applied to the dissection of disease pathology [20] and facilitating drug screening for personalized treatment [21, 22].”
BackgroundBioreactor Technologies for Enhanced Organoid Culture
Licata, J. P., Schwab, K. H., Har-el, Y.-E., Gerstenhaber, J. A., & Lelkes, P. I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411427 · Cited by 114
Knight, J. R. P., Alexandrou, C., Skalka, G. L., Vlahov, N., Pennel, K., Officer, L., Teodosio, A., Kanellos, G., Gay, D. M., May-Wilson, S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0652 · Cited by 96
“Finally, we applied MNK and mTORC1 inhibitors to two patient-derived organoid lines bearing deletion of APC and KRAS G12D mutations (52).”
Self-citationMicrofluidic Organoids-on-a-Chip: Quantum Leap in Cancer Research
Duzagac, F., Saorin, G., Memeo, L., Canzonieri, V., & Rizzolio, F. (2021) · Cancers · doi:10.3390/cancers13040737 · Cited by 96
“Gastrointestinal EGF/Noggin/R-spondin BMP-4 Gastrin A83-01 Y-27632 SB202190 Nicotinamide Matrigel Growth Factor Reduced-Matrigel BME * Collagen Collagen-Matrigel PEG Hydrogel [4] [46] [47] [70]”
BackgroundHeinzelmann, E., Piraino, F., Costa, M., Roch, A., Norkin, M. N., Garnier, V., Homicskó, K., & Brandenberg, N. (2024) · Current Research in Toxicology · doi:10.1016/j.crtox.2024.100197 · Cited by 114
“…heterogeneity including morphological heterogeneity, genetic heterogeneity, and heterogeneity in terms of drug response, which may be related to the different spectra of acquired mutations for each individual tumor (van de Wetering et al., 2015; Fujii et al., 2016; Vlachogiannis et al., 2018).”
Chadwick, M., Yang, C., Liu, L., Gamboa, C. M., Jara, K., Lee, H., & Sabaawy, H. E. (2020) · iScience · doi:10.1016/j.isci.2020.101365 · Cited by 101
Evolution of the Experimental Models of Cholangiocarcinoma
Massa, A., Varamo, C., Vita, F., Tavolari, S., Neia, C. P., Brandi, G., Rizzo, A., Cavalloni, G., & Aglietta, M. (2020) · Cancers · doi:10.3390/cancers12082308 · Cited by 96
Peritoneal Metastases From Colorectal Cancer: Defining and Addressing the Challenges
Kranenburg, O., der Speeten, K. V., & de Hingh, I. H. J. T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650098 · Cited by 102
Yao, Q., Cheng, S., Pan, Q., Yu, J., Cao, G., Li, L., & Cao, H. (2024) · MedComm · doi:10.1002/mco2.735 · Cited by 123
Zhang, F., Wang, W., Long, Y., Liu, H., Cheng, J., Guo, L., Li, R., Meng, C., Yu, S., Zhao, Q., et al. (2018) · 癌症:英文版 · doi:10.1186/s40880-018-0329-5 · Cited by 102
Schmidt, S., Gay, D. M., Uthe, F. W., Denk, S., Paauwe, M., Matthes, N., Diefenbacher, M. E., Bryson, S., Warrander, F., Erhard, F., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0408-0 · Cited by 108
Self-citationKim, S. K., Kim, Y. H., Park, S., & Cho, S.-W. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.03.002 · Cited by 94
Choi, Y.-M., Lee, H., Ann, M., Song, M., Rheey, J., & Jang, J. (2023) · Biofabrication · doi:10.1088/1758-5090/acd95f · Cited by 94
Karakasheva, T. A., Kijima, T., Shimonosono, M., Maekawa, H., Sahu, V., Gabre, J. T., Cruz‐Acuña, R., Giroux, V., Sangwan, V., Whelan, K. A., et al. (2020) · Current Protocols in Stem Cell Biology · doi:10.1002/cpsc.109 · Cited by 104
Breast Cancer Organoids Model Patient-Specific Response to Drug Treatment
Campaner, E., Zannini, A., Santorsola, M., Bonazza, D., Bottin, C., Cancila, V., Tripodo, C., Bortul, M., Zanconati, F., Schoeftner, S., et al. (2020) · Cancers · doi:10.3390/cancers12123869 · Cited by 92
“invaluable resource to study disease progression and test sensitivity to drug treatments [10,34].”
BackgroundClinical translation of patient-derived tumour organoids- bottlenecks and strategies
Foo, M. A., You, M., Chan, S. L., Sethi, G., Bonney, G. K., Yong, W.-P., Chow, E. K.-H., Fong, E. L. S., Wang, L., & Goh, B.-C. (2022) · Biomarker Research · doi:10.1186/s40364-022-00356-6 · Cited by 92
“Gastric Carcinoma 50% [41] 71% (10/14) [42] Metastatic Gastrointestinal Carcinoma 70% (> 100) [43]”
3D cancer models: One step closer to in vitro human studies
Manduca, N., Maccafeo, E., Maria, R. D., Sistigu, A., & Musella, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1175503 · Cited by 109
Qu, S., Xu, R., Yi, G., Li, Z., Zhang, H., Qi, S., & Huang, G. (2024) · Molecular Biomedicine · doi:10.1186/s43556-023-00165-9 · Cited by 117
“These PDOs can be derived from tumors at various stages of development and necessitate only a minor fraction of tumor tissue for establishment and subsequent in vitro expansion [55, 63, 103–111].”
BackgroundInfluentialLandscape of human organoids: Ideal model in clinics and research
Han, X., Cai, C., Deng, W., Shi, Y., Li, L., Wang, C., Zhang, J., Rong, M., Liu, J., Fang, B., et al. (2024) · The Innovation · doi:10.1016/j.xinn.2024.100620 · Cited by 162
“180 The aim of personalized medicine is to tailor treatments to individual patients based on their genetic and physiological characteristics.”
BackgroundEngineering Precision Medicine
Sun, W., Lee, J., Zhang, S., Benyshek, C., Dokmeci, M. R., & Khademhosseini, A. (2018) · Advanced Science · doi:10.1002/advs.201801039 · Cited by 103
Votanopoulos, K. I., Mazzocchi, A. R., Sivakumar, H., Forsythe, S. D., Aleman, J., Levine, E. A., & Skardal, A. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-7008-2 · Cited by 95
Three-dimensional cell culture: from evolution to revolution
Alhaque, S., Themis, M., & Rashidi, H. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2017.0216 · Cited by 97
Varayathu, H., Sarathy, V., Thomas, B. E., Mufti, S. S., & Naik, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.559161 · Cited by 104
Orthotopic and metastatic tumour models in preclinical cancer research
Stribbling, S. M., Beach, C., & Ryan, A. J. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108631 · Cited by 109
“Importantly, it has been shown that orthotopically implanted, patient-derived organoids have the potential to recapitulate patient responses in the clinic (Vlachogiannis et al., 2018).”
BackgroundBlack Phosphorus Quantum Dots Cause Nephrotoxicity in Organoids, Mice, and Human Cells
He, C., Ruan, F., Jiang, S., Zeng, J., Yin, H., Liu, R., Zhang, Y., Huang, L., Wang, C., Ma, S., et al. (2020) · Small · doi:10.1002/smll.202001371 · Cited by 90
Tosca, E. M., Ronchi, D., Facciolo, D., & Magni, P. (2023) · Biomedicines · doi:10.3390/biomedicines11041058 · Cited by 103
The Intestinal Epithelium – Fluid Fate and Rigid Structure From Crypt Bottom to Villus Tip
Bonis, V., Rossell, C., & Gehart, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.661931 · Cited by 113
Assessing Toxicity with Human Cell-Based In Vitro Methods
Zink, D., Chuah, J. K. C., & Ying, J. Y. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.01.008 · Cited by 100
Avci, N. G., Pustchi, S. E., Akay, Y. M., Esquenazi, Y., Tandon, N., Zhu, J., & Akay, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-70392-5 · Cited by 101
Papaccio, F., García-Micó, B., Gimeno-Valiente, F., Cabeza-Segura, M., Gambardella, V., Gutiérrez-Bravo, M. F., Alfaro‐Cervelló, C., Martínez‐Ciarpaglini, C., Rentero-Garrido, P., Zúñiga, S., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02591-z · Cited by 98
“They recapitulate the biology of original tumor tissue, including therapy response [6], and can be rapidly generated for many cancer types [7–10] with a lower cost than animal models.”
BackgroundHuman organoids as 3D in vitro platforms for drug discovery: opportunities and challenges
Wang, D., Villenave, R., Stokar‐Regenscheit, N., & Clevers, H. C. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01317-y · Cited by 130
Alexandrou, C., Al-Aqbi, S. S., Higgins, J. A., Boyle, W., Karmokar, A., Andreadi, C., Luo, J., Moore, D. A., Viskaduraki, M., Blades, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-30591-7 · Cited by 96
Current Status of Patient-Derived Ovarian Cancer Models
Maru, Y., & Hippo, Y. (2019) · Cells · doi:10.3390/cells8050505 · Cited by 95
The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization
Angerilli, V., Galuppini, F., Pagni, F., Fusco, N., Malapelle, U., & Fassan, M. (2021) · Diagnostics · doi:10.3390/diagnostics11020339 · Cited by 103
“Small-scale drug screens on organoids biobanks have yielded promising results, as PDOs seem to be able to recapitulate the patient’s response in the clinic, thus paving the way for the development of high-throughput screening [74].”
BackgroundSelf-citation3D tumor angiogenesis models: recent advances and challenges
Bhat, S. M., Badiger, V. A., Vasishta, S., Chakraborty, J., Seetharam, P., Ghosh, S., & Joshi, M. B. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03814-0 · Cited by 95
Organoid Models for Precision Cancer Immunotherapy
Sun, C., Lan, H., Fang, X., Yang, X., & Jin, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.770465 · Cited by 107
Mapping and modeling human colorectal carcinoma interactions with the tumor microenvironment
Li, N., Zhu, Q., Tian, Y., Ahn, K. J., Wang, X., Cramer, Z., Jou, J., Folkert, I. W., Yu, P., Adams‐Tzivelekidis, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43746-6 · Cited by 99
“SPP1 encodes the extracellular matrix component Osteopontin, whichactsasa CD44 ligand and has pleiotropicroles in tumor biology, most notably suppression of T cell activation 9 , and the SPP1+ macrophage state is associated with immune evasion and metastatic proclivity 15,21,22 .”
Dayton, T. L., Alcala, N., Moonen, L., den Hartigh, L., Geurts, V., Mangiante, L., Lap, L. M. V., Dost, A. F. M., Beumer, J., Levy, S., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.11.007 · Cited by 93
A patient-specific lung cancer assembloid model with heterogeneous tumor microenvironments
Zhang, Y., Hu, Q., Pei, Y., Luo, H., Wang, Z., Xu, X., Zhang, Q. H., Dai, J., Wang, Q., Fan, Z., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47737-z · Cited by 105
“Although some cancer organoids 71,72 and patient tumor-derived cell clusters 11 were reported to recapitulate patient responses in the clinic, the lack of inter-and intra-batch consistency and heterogeneous TME affects the ef fi ciency and accuracy of drug testing 73 .”
Deben, C., Hoz, E. C. D. L., Compte, M. L., Schil, P. E. V., Hendriks, J. M. H., Lauwers, P., Yogeswaran, S. K., Lardon, F., Pauwels, P., Laere, S. V., et al. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00750-0 · Cited by 97
“Furthermore, one of the most promising applications of 70 PDOs is for personalized cancer treatment to predict clinical response ex vivo (2-8).”
BackgroundWang, Q., Yuan, F., Zuo, X., & Li, M. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02505-w · Cited by 118
Cho, S., Yoon, C., Lee, J. H., Chang, K. K., Lin, J.-X., Kim, Y.-H., Kook, M., Aksoy, B. A., Park, D. J., Ashktorab, H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1679 · Cited by 85
“Growth factors for organoid culture were added to the following essential components (30): 0.”
BackgroundRetractedZhu, J., Ji, L., Chen, Y., Li, H., Huang, M., Dai, Z., Wang, J., Xiang, D., Fu, G., Lei, Z., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01354-9 · Cited by 93
“No response to cetuximab showed in its organoids consistent with the patient’s clinical response [67].”
BackgroundInfluentialIKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer
Colomer, C., Margalef, P., Villanueva, A., Vert, A., Pecharromán, I., Solé, L., Gonzàlez‐Farré, M., Alonso‐Marañón, J., Montagut, C. O., Martínez‐Iniesta, M., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.05.036 · Cited by 90
“To test this possibility, we treated patient-derived colorectal cancer (CRC) tumoroids (Figure 5A), which have been recently validated asmodels for therapy prescription (Sato et al., 2011; Vlachogiannis et al., 2018), with suboptimal doses of 5-FU+irinotecan (Iri), alone or in combination with the BRAF inhibitors vemu…”
BackgroundMethodTao, X.-Y., Li, Q., & Zeng, Y. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02063-2 · Cited by 104
“Previously, it was found that patient-derived organoids (PDOs) could predict patient’s response to targeted drugs when cancer cells derived from cancer patients are cultured in vitro [92].”
BackgroundThe clonal evolution of metastatic colorectal cancer
Dang, H. X., Krasnick, B. A., White, B. S., Grossman, J. G., Strand, M. S., Zhang, J., Cabanski, C. R., Miller, C. A., Fulton, R. S., Goedegebuure, S. P., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay9691 · Cited by 95
Role of Patient-Derived Models of Cancer in Translational Oncology
Idrisova, K., Simon, H., & Gomzikova, M. O. (2022) · Cancers · doi:10.3390/cancers15010139 · Cited by 92
“Numerous studies have shown a positive correlation between the in vitro response of organoids to drugs and corresponding response of primary tumors in vivo in both mice and humans [34,36,59].”
BackgroundLim, J., Ching, H., Yoon, J., Jeon, N. L., & Kim, Y. (2021) · Nano Convergence · doi:10.1186/s40580-021-00261-y · Cited by 91
Kerns, S. J., Belgur, C., Petropolis, D., Kanellias, M., Barrile, R., Sam, J., Weinzierl, T., Fauti, T., Freimoser-Grundschober, A., Eckmann, J., et al. (2021) · eLife · doi:10.7554/elife.67106 · Cited by 82
Mertens, S., Huismans, M. A., Veríssimo, C. S., Ponsioen, B., Overmeer, R., Proost, N., van Tellingen, O., van de Ven, M., Begthel, H., Boj, S. F., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112324 · Cited by 90
Organoid bioprinting: from cells to functional tissues
Huang, M. S., Christakopoulos, F., Roth, J. G., & Heilshorn, S. C. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00268-0 · Cited by 114
Zebrafish Avatars towards Personalized Medicine—A Comparative Review between Avatar Models
Costa, B. F., Estrada, M. F., Mendes, R. V., & Fior, R. (2020) · Cells · doi:10.3390/cells9020293 · Cited by 90
“There are 3 reports showing a correlation: 2 patients for breast cancer, 4 for gastrointestinal cancer, and 12 patients for colorectal cancer could be effectively matched to the organoid Avatar result [44,48,49].”
BackgroundFine-Needle Aspiration-Based Patient-Derived Cancer Organoids
Vilgelm, A. E., Bergdorf, K. N., Wolf, M. M., Bharti, V., Shattuck-Brandt, R. L., Blevins, A., Jones, C. Y., Phifer, C. J., Lee, M. A., Lowe, C. L., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101408 · Cited by 84
Hirt, C., Booij, T. H., Grob, L., Simmler, P., Toussaint, N. C., Keller, D., Taube, D., Ludwig, V., Goryachkin, A., Pauli, C., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100095 · Cited by 109
Standardization of organoid culture in cancer research
Zhou, C., Wu, Y., Wang, Z., Liu, Y., Yu, J., Wang, W., Chen, S., Wu, W., Wang, J., Qian, G., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5943 · Cited by 96
Construction of tumor organoids and their application to cancer research and therapy
Lv, J., Du, X., Wang, M., Su, J., Wei, Y., & Xu, C. (2024) · Theranostics · doi:10.7150/thno.91362 · Cited by 95
“Vlachogiannis et al. established a living biobank of tumor organoids from metastatic, heavily pretreated gastroesophageal and CRC patients recruited in phase 1/2 clinical trials [130].”
BackgroundHeterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures
Schumacher, D., Andrieux, G., Boehnke, K., Keil, M., Silvestri, A., Silvestrov, M., Keilholz, U., Haybaeck, J., Erdmann, G., Sachse, C., et al. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008076 · Cited by 80
“Since regorafenib specifically targets the tumor vasculature, any conclusions regarding the proliferation of organoids are very limited [14].”
Background3D Culture Systems for Exploring Cancer Immunology
Fitzgerald, A. A., Li, E., & Weiner, L. M. (2020) · Cancers · doi:10.3390/cancers13010056 · Cited by 91
“Organoids have been used to screen other drug classes, such as cytotoxic drugs and small molecule inhibitors [15,78].”
MethodA 3D View of Colorectal Cancer Models in Predicting Therapeutic Responses and Resistance
Reidy, E., Leonard, N. A., Treacy, O., & Ryan, A. E. (2021) · Cancers · doi:10.3390/cancers13020227 · Cited by 92
Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer
Toshimitsu, K., Takano, A., Fujii, M., Togasaki, K., Matano, M., Takahashi, S., Kanai∥, T., & Sato, T. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-00984-x · Cited by 91
Bridging live-cell imaging and next-generation cancer treatment
Alieva, M., Wezenaar, A. K. L., Wehrens, E. J., & Rios, A. C. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00610-5 · Cited by 98
“Patient-derived organoids (PDOs) recapitulate both architectural and genetic features of their original tissue specimen 125 , including patient-specific responses to treatment 126,127 , and therefore carry prospective value for predicting clinical outcomes in patients 128,129 .”
BackgroundPatient-derived xenografts (PDXs) as model systems for human cancer
Invrea, F., Rovito, R., Torchiaro, E., Petti, C., Isella, C., & Médico, E. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.01.003 · Cited by 85
Atat, O. E., Farzaneh, Z., Pourhamzeh, M., Taki, F., Abi‐Habib, R. J., Vosough, M., & El‐Sibai, M. (2021) · Human Cell · doi:10.1007/s13577-021-00642-9 · Cited by 87
“This study proposed that the utility of PDO in pre-clinical studies was useful for drug screening and for predicting the efficacy of drugs, and thus, PDO would serve as an important tool in personalized medicine [105].”
BackgroundMethodClinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions
Macías, R. I. R., Cardinale, V., Kendall, T. J., Avila, M. A., Guido, M., Coulouarn, C., Braconi, C., Frampton, A. E., Bridgewater, J. A., Overi, D., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-327099 · Cited by 91
Self-citationApplications of human organoids in the personalized treatment for digestive diseases
Wang, Q., Guo, F., Jin, Y., & Ma, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01194-6 · Cited by 78
“To continuously optimize clinical treatment strategies and explore the pathogenesis of diseases, organoid biobanks for various diseases have been established in recent years, among which gene mutation-related diseases and malignant tumors are the most common.(303,323,324,456) For example, organoid biobanks derived fro…”
BackgroundMethodInfluentialStrelez, C., Chilakala, S., Ghaffarian, K., Lau, R., Spiller, E. R., Ung, N. M., Hixon, D., Yoon, A. Y., Sun, R., Lenz, H., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102509 · Cited by 91
Bollen, Y., Stelloo, E., van Leenen, P., van den Bos, M., Ponsioen, B., Lu, B., van Roosmalen, M. J., Bolhaqueiro, A. C. F., Kimberley, C., Mossner, M., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00891-2 · Cited by 83
Self-citationGao, M., Lin, M., Rao, M., Thompson, H., Hirai, K., Choi, M., Georgakis, G. V., Sasson, A. R., Bucobo, J. C., Tzimas, D. J., et al. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6662-8 · Cited by 88
Enabling peristalsis of human colon tumor organoids on microfluidic chips
Fang, G., Lu, H., Al-Nakashli, R., Chapman, R., Zhang, Y., Ju, L. A., Lin, G., Stenzel, M. H., & Jin, D. (2022) · Biofabrication · doi:10.1088/1758-5090/ac2ef9 · Cited by 77
“Vlachogiannis et al developed organoids culture from colorectal, gastroesophageal, or cholangiocarcinoma patients, and they found 100% sensitivity, 93% specificity, 88% positive predictive value, and 100% negative predictive value in forecasting response to targeted agents or chemotherapy in patients [2].”
Executable cancer models: successes and challenges
Clarke, M. A., & Fisher, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0258-x · Cited by 88
Druggable genome and precision medicine in cancer: current challenges
Dupont, C., Riegel, K., Pompaiah, M., Juhl, H. H., & Rajalingam, K. (2021) · FEBS Journal · doi:10.1111/febs.15788 · Cited by 86
Immune organoids: from tumor modeling to precision oncology
Dao, V. A., Yuki, K., Lo, Y., Nakano, M., & Kuo, C. J. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.06.001 · Cited by 83
Mathematical Models of Organoid Cultures
Montes-Olivas, S., Marucci, L., & Homer, M. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00873 · Cited by 80
Forsythe, S. D., Erali, R. A., Sasikumar, S., Laney, P., Shelkey, E., D'Agostino, R., Miller, L. D., Shen, P., Levine, E. A., Soker, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0982 · Cited by 75
“Application of PTOs in metastatic colorectal and gastroesophageal cancer enrolled in phase I/II clinical trials, recapitulated patient response to chemotherapy with an 88% positive predictive value and 100% negative predictive value (8).”
BackgroundPersonalized chordoma organoids for drug discovery studies
Al Shihabi, A., Davarifar, A., Nguyen, H. T. L., Tavanaie, N., Nelson, S. D., Yanagawa, J., Federman, N., Bernthal, N., Hornicek, F., & Soragni, A. (2022) · Science Advances · doi:10.1126/sciadv.abl3674 · Cited by 75
Nanotheranostics Targeting the Tumor Microenvironment
Roma‐Rodrigues, C., Pombo, I., Raposo, L. R., Pedrosa, P., Fernandes, A. R., & Baptista, P. V. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00197 · Cited by 84
Addressing Patient Specificity in the Engineering of Tumor Models
Bray, L. J., Hutmacher, D. W., & Bock, N. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00217 · Cited by 73
“While the variations that occur between batches of Matrigel hinder the reproducibility of the organoid cultures (Postovit, 2016), the engineering of various semi-synthetic and synthetic matrices (Bray et al., 2017, 2018; Romero-López et al., 2017; Wang et al., 2019) may be able to build a new platform from the bottom-…”
BackgroundMethodInfluentialChen, J., Chu, X., Zhang, J., Nie, Q., Tang, W., Su, J., Yan, H., Zheng, H., Chen, Z., Chen, X., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13542 · Cited by 75
Dissecting metastasis using preclinical models and methods
Hebert, J. D., Neal, J. W., & Winslow, M. M. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00568-4 · Cited by 86
Zhou, Z., Pang, Y., Ji, J., He, J., Liu, T., Ouyang, L., Zhang, W., Zhang, X., Zhang, Z., Zhang, K., et al. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00896-4 · Cited by 84
“Depending on the kind of cancer that is cultured, various factors (such as WNT3A) and/or pathway inhibitors are supplemented to the medium in Matrigel embedding culture 72,78,82 .”
Metadata
- Authors
- Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., Rata, M., Koh, D.-M., Tunariu, N., Collins, D., Hulkki-Wilson, S., Ragulan, C., Spiteri, I., Moorcraft, S. Y., Chau, I., Rao, S., Watkins, D., Fotiadis, N., Bali, M., Darvish-Damavandi, M., Lote, H., Eltahir, Z., Smyth, E. C., Begum, R., Clarke, P. A., Hahne, J. C., Dowsett, M., de Bono, J., Workman, P., Sadanandam, A., Fassan, M., Sansom, O. J., Eccles, S., Starling, N., Braconi, C., Sottoriva, A., Robinson, S. P., Cunningham, D., & Valeri, N.
- Affiliations
- Institute of Cancer Research (GB)
- Royal Marsden NHS Foundation Trust (GB)
- Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
- Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Trust, London, UK.
- Division of Clinical Studies, The Institute of Cancer Research, London, UK.
- University of Padua (IT)
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Valeri, Nicola
- ORCID
- Vlachogiannis, Georgios
- Hedayat, Somaieh
- Jamin, Yann
- Fernández-Mateos, Javier
- Khan, Khurum
- Lampis, Andrea
- Eason, Katherine
- Huntingford, Ian
- Burke, Rosemary
- Rata, Mihaela
- Koh, Dow-Mu
- Tunariu, Nina
- Collins, David
- Ragulan, Chanthirika
- Spiteri, Inmaculada
- Moorcraft, Sing Yu
- Chau, Ian
- Rao, Sheela
- Watkins, David
- Fotiadis, Nicos
- Bali, Maria
- Darvish-Damavandi, Mahnaz
- Lote, Hazel
- Eltahir, Zakaria
- Smyth, Elizabeth C.
- Begum, Ruwaida
- Clarke, Paul A.
- Hahne, Jens C.
- Workman, Paul
- Sadanandam, Anguraj
- Fassan, Matteo
- Sansom, Owen J.
- Starling, Naureen
- Braconi, Chiara
- Sottoriva, Andrea
- Robinson, Simon P.
- Cunningham, David
- Valeri, Nicola
- Venue
- Science
- Published
- 2018-02-23
- Volume
- 359
- Issue
- 6378
- Pages
- 920-926
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6112415
- OpenAlex
- W2788735115
- Cited by
- 2,096
- References
- 36
- Citations by year
- 2026: 318 · 2025: 286 · 2024: 282 · 2023: 234 · 2022: 262 · 2021: 294 · 2020: 207 · 2019: 124 · 2018: 87
- FWCI
- 66.95
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- FP7 People: Marie-Curie Actions (CIG334261)
- National Institute for Health Research (A62)
- Cancer Research UK (CEA A18052)
- European Commission (Marie Curie CIG 618154)
- European Research Council (331301)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Keywords
- patient-derived organoids, metastatic gastrointestinal cancer, colorectal cancer, gastroesophageal cancer, treatment response prediction, drug screening, tumor organoids, orthotopic xenograft, personalized medicine, biobanks, molecular profiling, anticancer agents
- MeSH terms
- Animals, Antineoplastic Agents, Gastrointestinal Neoplasms, Humans, Neoplasm Metastasis, Organoids, Phenylurea Compounds, Pyridines, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Genomics, Mice, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.